SEC Form 4 · accession 0001193125-26-300923
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew R Henn
Officer — See Remarks
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.13 | Jul 8, 2026 | A | 25,000 | A | — | Mar 3, 2036 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Remarks
President and Chief Scientific Officer